Clinical Trials

166 enrolled

Multiple Myeloma

NCT04739813 2026-06-01

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

34 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Other hematologic neoplasmPlasma cell

18 enrolled

Leukemia, Plasma Cell, Multiple Myeloma

NCT01955499 2026-05-13

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

39 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02160015 2026-05-13

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

LymphoidOther hematologic neoplasm

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01711554 2026-04-13

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

27 enrolled

CNS

Neuroblastoma

NCT06192888 2026-03-27

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

39 enrolled

Lymphoma, Mantle-Cell

NCT02446236 2026-03-24

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

27 enrolled 11 charts

Lymphoma, Mantle-Cell

NCT02573896 2026-03-23

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

13 enrolled

CNS

Neuroblastoma

NCT02886065 2026-03-13

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

19 enrolled

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT03070327 2026-03-04

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

20 enrolled

Multiple Myeloma

NCT01562405 2026-01-14

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

33 enrolled

Multiple Myeloma, Recurrence

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

283 enrolled

Multiple Myeloma, Neoplasms

NCT04091126 2025-11-28

DREAMM 9

118 enrolled

Multiple Myeloma

NCT04447716 2025-09-15

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

4 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02992522 2025-09-09

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

22 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT05308654 2025-08-14

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

34 enrolled

Multiple Myeloma, Neoplasms

NCT06547944 2024-08-09

ZGR in TN CLL